TRELSTAR Drug Patent Profile

When do Trelstar patents expire, and when can generic versions of Trelstar launch?

Trelstar is a drug marketed by Verity and is included in three NDAs. There is one patent protecting this drug.

This drug has forty-seven patent family members in thirty-two countries.

The generic ingredient in TRELSTAR is triptorelin pamoate. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the triptorelin pamoate profile page.

DrugPatentWatch^® Generic Entry Outlook for Trelstar

Trelstar was eligible for patent challenges on June 15, 2004.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 30, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for TRELSTAR

International Patents:	47
US Patents:	1
Applicants:	1
NDAs:	3

US Patents and Regulatory Information for TRELSTAR

TRELSTAR is protected by one US patents.

This potential generic entry date is based on patent 10,166,181.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	020715-001	Jun 15, 2000		RX	Yes	Yes
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	021288-001	Jun 29, 2001		RX	Yes	Yes
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	022437-001	Mar 10, 2010		RX	Yes	Yes	10,166,181		Y

International Patents for TRELSTAR

When does loss-of-exclusivity occur for TRELSTAR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Australia

Brazil

Canada

China

Colombia

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Poland

Portugal

Serbia

Slovenia

South Africa

South Korea

Spain

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRELSTAR around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	397197
Austria	397198
Austria	A154590
Austria	A223591
Australia	5910390

Trelstar (triptorelin) investment scenario and fundamentals: exclusivity, patent landscape, FDA status, and generic risk

Last updated: July 26, 2026

Executive summary: Trelstar (triptorelin) is a long-established GnRH agonist franchise for advanced prostate cancer and is also used in other indications depending on formulation and label. Investment fundamentals are driven by (1) the remaining patent and regulatory exclusivity perimeter around each depot product strength, (2) whether FDA/Orange Book lists are still being challenged via Paragraph IV filings or settled via licensing, (3) competitive pressure from other triptorelin depots and leuprolide-based alternatives, and (4) manufacturing and device-like complexity for extended-release microspheres. The near-term investment case is typically tied to sustained oncology depot demand and the depth and survivability of formulation and method-of-use intellectual property rather than any single “composition” asset.

What patents protect Trelstar (triptorelin) depot products, and how many are still enforceable?

Short answer: Trelstar’s enforceable perimeter is usually split across (a) composition of matter around triptorelin itself (often older and closer to expiry), (b) depot formulation and microsphere-related patents (often later), (c) manufacturing process patents (control of particle size, release profile, and sterility assurance), and (d) method-of-use and dosing regimen patents tied to advanced prostate cancer endpoints. The practical protection set most relevant to investors is the number of active Orange Book-listed patents per marketed strength and the number of unexpired secondary patents that still map to the specific NDA strengths and dosage forms.

How to think about the Trelstar patent estate by asset type

A. Composition of matter

• Historically, GnRH analog composition patents can expire earlier than depot-specific IP.
• If composition-of-matter is exhausted, investors focus on formulation and process barriers that sustain market exclusivity against AB-rated generics.

B. Depot formulation patents Key claim themes include:

• PLGA or other polymer microsphere composition
• particle size distribution
• drug loading and crystallinity state at fill
• in vitro and in vivo release kinetics tied to the specific depot interval (1 month, 3 months)
• excipient systems controlling re-suspension and injectability

C. Manufacturing method patents

• solvent evaporation/encapsulation method
• spray drying vs emulsification pathways
• control strategies for residual solvent and residual polymer impurities
• sterilization validation and batch release testing

D. Method-of-use and dosing regimen patents

• dosing schedules for advanced prostate cancer
• combination regimens (less common for older depot products but seen across GnRH agonists)

Patent “count” matters, but enforceability matters more

For an investment model, the metric is not simply how many patents exist; it is:

• how many are listed in the FDA Orange Book for each depot strength and whether they are still unexpired,
• how many are subject to litigation (and therefore have survival odds under court interpretation),
• whether patents are tied to the exact claim cover the competitor’s chosen formulation route.

Jurisdiction footprint

Trelstar is typically litigated in the US for Orange Book exclusivity and at-the-time product launches. For a global investment scenario, the same formulation IP patterns usually exist in EP and national filings, but the US is the gating factor for generic entry timelines under FDA.

When does Trelstar lose exclusivity, and what are the key timeline drivers for investors?

Short answer: The exclusivity timeline for Trelstar depends on (1) the last eligible approval date for each NDA strength/formulation, (2) patent expiration dates of Orange Book-listed patents for those strengths, and (3) any periods of regulatory exclusivity that attach to specific changes (new indication, new dosage form, or supplemental approvals). The investment calendar is built from the latest “hard” date (patent expiry) plus the “soft” calendar from generic challenge pathways.

Timeline model investors use for depot oncology products

1) Patent expiration (hard stop for generic approvals if still enforceable)

• Investors track earliest and last expiry among Orange Book-listed patents per strength.
• The last-to-expire listed patent typically blocks AB substitution until expiry or successful challenge.

2) Regulatory exclusivity (soft but real)

• Some supplemental exclusivities can extend the earliest permissible competition.
• For extended-release injectables, regulatory exclusivity often follows post-approval manufacturing changes or new depot strengths.

3) Paragraph IV milestones

• If a generic files a Paragraph IV certification, the launch depends on litigation outcome and settlement terms.
• Even without an active settlement, litigation can create a de facto delay.

The practical investor calendar

The core decision checkpoints are:

• whether Orange Book listings show late-expiring formulation/process patents,
• whether Paragraph IV filings appear in the same NDA and dosage strength,
• whether courts have already construed key claim limitations affecting generic design-around viability.

What is the Orange Book status of Trelstar, and which patents are listed for each dosage strength?

Short answer: Investors need the Orange Book mapping by strength (often the 1-month and 3-month depots for advanced prostate cancer). The Orange Book status for Trelstar should be treated as a set of patent “layers” rather than one blanket expiration date. Each strength can have a distinct listing stack, and investors should price the last-to-expire listed patent per strength.

What to extract from the Orange Book for an investment model

• NDA number(s)
• dosage form and strength
• active listed patents and their expiration dates
• patent type categories (for modeling generic risk)
• exclusivity code and expiration date (if listed)

Why Orange Book mapping drives valuations

A generic entrant’s strategy usually targets one dosage strength or all strengths depending on feasibility. If Trelstar has staggered patent expiry by strength, competition can be partial (one strength first), causing margin compression without full franchise loss.

What generic entry risks exist for Trelstar, and how likely are Paragraph IV challenges to lead to earlier launches?

Short answer: For depot injectables, the generic risk is shaped by how easily competitors can meet:

• release-profile requirements,
• particle/microsphere and polymer-related claim limitations,
• sterility and injectability specifications for depot products. Generic entry timelines are usually advanced only when competitors successfully challenge formulation or manufacturing patents, or when those patents are not enforced strongly.

Generic entry risk factors specific to depot GnRH agonists

• Formulation replication complexity: Extended-release depot microspheres are not interchangeable by simple ratio changes.
• Bioequivalence burden: While AB substitution uses approved bioequivalence standards, depot products can face tighter scrutiny around release kinetics.
• Design-around feasibility: Competitors can sometimes shift polymer type, manufacturing method, or particle size distributions. If patents claim genus-level ranges, design-around is harder.

Paragraph IV outcome pathways

• No challenge: generic stays blocked until patent expiry.
• Challenge but defeat: launch delayed through court ruling.
• Settlement: entry can be set by date and sometimes conditioned on product launch labeling and manufacturing.

Which companies are challenging Trelstar, and what is the status of Trelstar patent litigation?

Short answer: The litigation-driven part of the Trelstar risk model depends on the docket status of any Paragraph IV suits linked to Orange Book-listed patents. The most decision-relevant variables are:

• which patents were asserted,
• claim construction outcomes,
• whether settlements exist and the stated earliest launch date.

How to convert litigation into investment signals

• If courts uphold broad formulation/process claim scope, investor downside increases because generic design-arounds face higher failure probability.
• If courts narrow claim interpretation to specific parameters (like particle size range), investor upside increases because generic entrants may still have viable design-around formulation paths.

Settlement-driven entry risk

If a settlement is reached, it can:

• accelerate or cap competition relative to the last-to-expire patent,
• force design constraints on the generic (strength, labeling, or manufacturing method).

How does Trelstar compare with leuprolide and other GnRH agonists on patent and commercial durability?

Short answer: Within advanced prostate cancer, GnRH agonists form a crowded class. Trelstar’s relative durability depends on how quickly competitors gain depot-interval preference and reimbursement position, not just patent protection. Even with patents intact, competitive pressure can reduce share through:

• payer behavior toward specific depot interval,
• patient and physician selection based on dosing schedule,
• supply reliability and switching programs.

Competitive substitution map investors track

• triptorelin depots vs leuprolide depots (and other GnRH agonists)
• 1-month vs 3-month interval preferences
• billing codes and reimbursement differentials

What matters for forecast accuracy

• pricing and net-to-gross trends across oncology injectables
• channel inventory behavior around settlement or supply disruption
• tender and contract pricing by health systems

What formulations are protected for Trelstar, and what dosage forms face the highest generic risk?

Short answer: The highest generic risk is typically tied to the most actively commercialized depot strength and the formulation layers that are both Orange Book listed and central to depot release performance. Formulation patents that claim specific microsphere architecture and release kinetics are usually the hardest to design around.

Depot strength considerations

• 1-month depot products can face different development and patent mapping versus 3-month depots due to distinct polymer loadings and release profiles.
• If patent layers are staggered, the commercial risk can be stepped rather than a single “cliff.”

Manufacturing/IP barriers that create switching resistance

• validated aseptic processing
• batch-to-batch release controls
• residual impurities and sterilization method constraints

What patent litigation affects FDA approval timing for Trelstar generics and biosimilar-style entrants?

Short answer: For Trelstar, the relevant mechanism is ANDA Paragraph IV exclusivity and patent infringement litigation. Biosimilars do not apply because triptorelin is a small-molecule peptide drug product, not a biologic. The investment impact flows through:

• statutory 30-month stay risk after Paragraph IV filing,
• court injunction likelihood affecting launch,
• settlement terms controlling launch design and timing.

What is the FDA regulatory status of Trelstar, and what milestones matter for competitive entry?

Short answer: The regulatory gating for generic entry is tied to the NDA status, Orange Book listings, and any prior approval changes that create new exclusivity. Investors track:

• the NDA approval history,
• any recent manufacturing supplement approvals,
• any newly listed patents associated with manufacturing changes that can extend blocking.

FDA review pathway signals investors monitor

• whether the NDA has received supplements tied to formulation or manufacturing changes,
• whether any additional NDA strengths or pack configurations were approved,
• whether labeling changes coincide with new patent listings.

Commercial fundamentals: what drives Trelstar revenue durability in oncology depots?

Short answer: For investors, the commercialization model for Trelstar depot injectables hinges on:

• patient persistence on androgen deprivation therapy (ADT),
• dosing interval preference and adherence,
• payer coverage and net price trajectory,
• distribution reliability for depot injectables.

Demand drivers

• incidence and treatment intensity in advanced prostate cancer
• clinical positioning across line-of-therapy
• prescriber familiarity and switching friction between depot products

Revenue risk drivers

• net price erosion from competitive depot offerings
• channel stocking behavior ahead of competitive entries
• supply constraints in manufacturing of depot microspheres

Key investment scenario outcomes for Trelstar: base, bull, bear

Base case: Franchise durability persists while key Orange Book-listed formulation/process patents remain enforceable through the modeled horizon. Generic entry risk remains real but delayed by depot formulation complexity and any active litigation.

Bull case: Litigation narrows claim scope or settlements cap generic entry later than the earliest patent-expiry date. Brand retains pricing and share, with incremental demand from interval adherence and stable reimbursement.

Bear case: Strong generic challenges result in early design-around success, loss of injunction leverage, and earlier-than-modeled launch under settlement or court outcomes. Margin compression accelerates through net price reductions and share loss.

Key Takeaways

• Trelstar’s investment case depends on the unexpired Orange Book-listed patent stack by depot strength, especially formulation and manufacturing layers.
• The next material catalysts are Paragraph IV activity, litigation outcomes (claim construction and injunctions), and settlement-triggered launch dates.
• Commercial durability is not only a patent story; payer coverage, interval preference, and depot manufacturing reliability drive net price and persistence.
• The highest generic risk is concentrated in the most commercially used strength whose formulation/process patents are both Orange Book listed and central to depot release performance.

FAQs

1. How do Orange Book-listed formulation patents block ANDA approval for triptorelin depot injectables like Trelstar?
2. What settlement terms most affect generic launch timing for Trelstar (entry date, labeling, manufacturing constraints)?
3. Which Trelstar depot strength faces the earliest generic launch risk if patents expire at different times?
4. How does depot microsphere manufacturing complexity influence bioequivalence and design-around strategies for generic triptorelin?
5. What competitive substitution dynamics matter most for Trelstar versus leuprolide depots in advanced prostate cancer?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-07-26).
2. FDA. 21 CFR 314.94 and 30-month stay framework for Paragraph IV ANDA litigation. (Accessed 2026-07-26).
3. FDA. Approved drug products and NDA status datasets. (Accessed 2026-07-26).